• Consensus Rating: Buy
  • Consensus Price Target: $5.33
  • Forecasted Upside: 107.52%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.57
▼ -0.08 (-3.02%)

This chart shows the closing price for CGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Compugen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEN

Analyst Price Target is $5.33
▲ +107.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Compugen in the last 3 months. The average price target is $5.33, with a high forecast of $8.00 and a low forecast of $4.00. The average price target represents a 107.52% upside from the last price of $2.57.

This chart shows the closing price for CGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Compugen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/19/2023Stifel NicolausBoost TargetBuy ➝ Buy$3.00 ➝ $4.00Low
8/23/2023Truist FinancialReiterated RatingBuy ➝ Buy$4.00Low
2/28/2023SVB LeerinkReiterated RatingOutperformLow
2/28/2023OppenheimerReiterated RatingOutperform$8.00Low
2/8/2023Jefferies Financial GroupDowngradeHold ➝ UnderperformLow
1/5/2023EF Hutton Acquisition Co. IInitiated CoverageBuy$13.00Low
11/14/2022OppenheimerLower TargetOutperform$12.00 ➝ $8.00Low
8/23/2022Truist FinancialLower TargetBuy$14.00 ➝ $4.00Low
8/8/2022JMP SecuritiesLower TargetMarket Outperform$8.00 ➝ $4.00Low
8/8/2022OppenheimerLower TargetOutperform$14.00 ➝ $12.00Low
8/5/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$2.00Low
2/25/2022OppenheimerLower TargetOutperform$17.00 ➝ $14.00Medium
2/25/2022SVB LeerinkLower TargetOutperform$16.00 ➝ $9.00Medium
11/15/2021JMP SecuritiesReiterated RatingBuy$18.00High
5/18/2021SVB LeerinkReiterated RatingBuy$16.00High
4/6/2021SVB LeerinkLower TargetOutperform$19.00 ➝ $16.00Low
3/17/2021OppenheimerReiterated RatingBuy$19.00High
8/19/2020SVB LeerinkBoost TargetOutperform$15.00 ➝ $19.00High
8/11/2020Jefferies Financial GroupReiterated RatingBuy$20.00Low
7/30/2020OppenheimerInitiated CoverageBuy$19.00High
5/26/2020JMP SecuritiesInitiated CoverageOutperform$18.00High
5/13/2020Stifel NicolausInitiated CoverageBuy$19.00High
5/7/2020SVB LeerinkInitiated CoverageOutperform$15.00High
4/28/2020SunTrust BanksBoost TargetPositive ➝ Buy$16.00 ➝ $22.00High
4/27/2020OppenheimerReiterated RatingBuy$15.00High
4/22/2020Roth CapitalInitiated CoverageBuy$28.00Medium
3/24/2020SunTrust BanksInitiated CoverageBuy$16.00High
2/21/2020Cantor FitzgeraldReiterated RatingOverweight$10.00 ➝ $13.00High
1/15/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/2/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
9/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
10/31/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
11/30/2023
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/30/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/28/2024

Current Sentiment

  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Compugen logo
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Read More

Today's Range

Now: $2.57
Low: $2.53
High: $2.67

50 Day Range

MA: $2.09
Low: $1.68
High: $2.65

52 Week Range

Now: $2.57
Low: $0.53
High: $2.85

Volume

515,615 shs

Average Volume

730,138 shs

Market Capitalization

$222.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.66

Frequently Asked Questions

What sell-side analysts currently cover shares of Compugen?

The following Wall Street research analysts have issued reports on Compugen in the last year: Oppenheimer Holdings Inc., Stifel Nicolaus, StockNews.com, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for CGEN.

What is the current price target for Compugen?

3 Wall Street analysts have set twelve-month price targets for Compugen in the last year. Their average twelve-month price target is $5.33, suggesting a possible upside of 107.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting CGEN will reach $8.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $4.00 for Compugen in the next year.
View the latest price targets for CGEN.

What is the current consensus analyst rating for Compugen?

Compugen currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGEN will outperform the market and that investors should add to their positions of Compugen.
View the latest ratings for CGEN.

What other companies compete with Compugen?

How do I contact Compugen's investor relations team?

Compugen's physical mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The biotechnology company's listed phone number is (723) 765-8585 and its investor relations email address is [email protected]. The official website for Compugen is www.cgen.com. Learn More about contacing Compugen investor relations.